Anticancer efficacy of allogeneic vaccine modified with progenitor neural cells supernatant in rats with glioma 101.8

The aim of the work was to investigate the antitumor efficacy of allogeneic tumor vaccine (ATV) modified with rat progenitor neural cell supernatant (RPNS) in rats with glioma 101.8. Materials and Methods: The study was performed on 74 white random-bred rats. ATV was developed on the basis of glioma...

Повний опис

Збережено в:
Бібліографічні деталі
Опубліковано в: :Experimental Oncology
Дата:2015
Автори: Liubich, L.D., Lisyany, M.I.
Формат: Стаття
Мова:Англійська
Опубліковано: Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України 2015
Теми:
Онлайн доступ:https://nasplib.isofts.kiev.ua/handle/123456789/145489
Теги: Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!
Назва журналу:Digital Library of Periodicals of National Academy of Sciences of Ukraine
Цитувати:Anticancer efficacy of allogeneic vaccine modified with progenitor neural cells supernatant in rats with glioma 101.8 / L.D. Liubich, M.I. Lisyany // Experimental Oncology. — 2015. — Т. 37, № 3. — С. 203-207. — Бібліогр.: 32 назв. — англ.

Репозитарії

Digital Library of Periodicals of National Academy of Sciences of Ukraine
_version_ 1862737670828982272
author Liubich, L.D.
Lisyany, M.I.
author_facet Liubich, L.D.
Lisyany, M.I.
citation_txt Anticancer efficacy of allogeneic vaccine modified with progenitor neural cells supernatant in rats with glioma 101.8 / L.D. Liubich, M.I. Lisyany // Experimental Oncology. — 2015. — Т. 37, № 3. — С. 203-207. — Бібліогр.: 32 назв. — англ.
collection DSpace DC
container_title Experimental Oncology
description The aim of the work was to investigate the antitumor efficacy of allogeneic tumor vaccine (ATV) modified with rat progenitor neural cell supernatant (RPNS) in rats with glioma 101.8. Materials and Methods: The study was performed on 74 white random-bred rats. ATV was developed on the basis of glioma 101.8 cell suspension modified with RPNS (0.02 or 0.10 mg/ml). RPNS was prepared from suspension made from whole rat brain tissue on 14th (E14) day of gestation. Model of brain glioma 101.8 was reproduced by intracerebral injection of glioma 101.8 cell suspension. ATV was injected intraperitoneally in a volume of 0.2 ml per animal once on the 10th day after tumor transplantation. For survival analysis Kaplan — Mayer multiple assessments method was used. Cytotoxic activity of rat lymphocytes (effector cells) was evaluated in MTT-colorimetric test by determining the state of mitochondrial dehydrogenase enzymes in target cells (allogeneic glioma 101.8 cells). Results: Intraperitoneal administration of ATV modified with 0.10 mg/ml RPNS significantly increased mean survival time and median survival of glioma-bearing rats compared with unvaccinated group (MST (19.9 ± 2.4), 21.4 days; versus MST (14.6 ± 2.8); 14 days; p = 0.0002, Gehan’s — Wilcoxon test). Intraperitoneal administration of ATV modified with 0.10 mg/ml RPNS resulted in increased cytotoxic activity of immune cells of rats with glioma in vitro compared with this index in unvaccinated group (p = 0.026, U-Mann — Whitney test). Conclusion: Antitumor effect of vaccination with RPNS-modified ATV is realized via increased cytotoxic activity of immune cells, what could be used for further optimization of whole tumor cell vaccine. Key Words: allogeneic tumor vaccine, rat progenitor neural cells supernatant, glioma 101.8, mean survival time, lymphocyte cytotoxic function.
first_indexed 2025-12-07T20:00:32Z
format Article
fulltext
id nasplib_isofts_kiev_ua-123456789-145489
institution Digital Library of Periodicals of National Academy of Sciences of Ukraine
issn 1812-9269
language English
last_indexed 2025-12-07T20:00:32Z
publishDate 2015
publisher Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
record_format dspace
spelling Liubich, L.D.
Lisyany, M.I.
2019-01-22T12:59:05Z
2019-01-22T12:59:05Z
2015
Anticancer efficacy of allogeneic vaccine modified with progenitor neural cells supernatant in rats with glioma 101.8 / L.D. Liubich, M.I. Lisyany // Experimental Oncology. — 2015. — Т. 37, № 3. — С. 203-207. — Бібліогр.: 32 назв. — англ.
1812-9269
https://nasplib.isofts.kiev.ua/handle/123456789/145489
The aim of the work was to investigate the antitumor efficacy of allogeneic tumor vaccine (ATV) modified with rat progenitor neural cell supernatant (RPNS) in rats with glioma 101.8. Materials and Methods: The study was performed on 74 white random-bred rats. ATV was developed on the basis of glioma 101.8 cell suspension modified with RPNS (0.02 or 0.10 mg/ml). RPNS was prepared from suspension made from whole rat brain tissue on 14th (E14) day of gestation. Model of brain glioma 101.8 was reproduced by intracerebral injection of glioma 101.8 cell suspension. ATV was injected intraperitoneally in a volume of 0.2 ml per animal once on the 10th day after tumor transplantation. For survival analysis Kaplan — Mayer multiple assessments method was used. Cytotoxic activity of rat lymphocytes (effector cells) was evaluated in MTT-colorimetric test by determining the state of mitochondrial dehydrogenase enzymes in target cells (allogeneic glioma 101.8 cells). Results: Intraperitoneal administration of ATV modified with 0.10 mg/ml RPNS significantly increased mean survival time and median survival of glioma-bearing rats compared with unvaccinated group (MST (19.9 ± 2.4), 21.4 days; versus MST (14.6 ± 2.8); 14 days; p = 0.0002, Gehan’s — Wilcoxon test). Intraperitoneal administration of ATV modified with 0.10 mg/ml RPNS resulted in increased cytotoxic activity of immune cells of rats with glioma in vitro compared with this index in unvaccinated group (p = 0.026, U-Mann — Whitney test). Conclusion: Antitumor effect of vaccination with RPNS-modified ATV is realized via increased cytotoxic activity of immune cells, what could be used for further optimization of whole tumor cell vaccine. Key Words: allogeneic tumor vaccine, rat progenitor neural cells supernatant, glioma 101.8, mean survival time, lymphocyte cytotoxic function.
en
Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
Experimental Oncology
Original contributions
Anticancer efficacy of allogeneic vaccine modified with progenitor neural cells supernatant in rats with glioma 101.8
Article
published earlier
spellingShingle Anticancer efficacy of allogeneic vaccine modified with progenitor neural cells supernatant in rats with glioma 101.8
Liubich, L.D.
Lisyany, M.I.
Original contributions
title Anticancer efficacy of allogeneic vaccine modified with progenitor neural cells supernatant in rats with glioma 101.8
title_full Anticancer efficacy of allogeneic vaccine modified with progenitor neural cells supernatant in rats with glioma 101.8
title_fullStr Anticancer efficacy of allogeneic vaccine modified with progenitor neural cells supernatant in rats with glioma 101.8
title_full_unstemmed Anticancer efficacy of allogeneic vaccine modified with progenitor neural cells supernatant in rats with glioma 101.8
title_short Anticancer efficacy of allogeneic vaccine modified with progenitor neural cells supernatant in rats with glioma 101.8
title_sort anticancer efficacy of allogeneic vaccine modified with progenitor neural cells supernatant in rats with glioma 101.8
topic Original contributions
topic_facet Original contributions
url https://nasplib.isofts.kiev.ua/handle/123456789/145489
work_keys_str_mv AT liubichld anticancerefficacyofallogeneicvaccinemodifiedwithprogenitorneuralcellssupernatantinratswithglioma1018
AT lisyanymi anticancerefficacyofallogeneicvaccinemodifiedwithprogenitorneuralcellssupernatantinratswithglioma1018